beta-lactams has been researched along with moxifloxacin in 21 studies
| Studies (beta-lactams) | Trials (beta-lactams) | Recent Studies (post-2010) (beta-lactams) | Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) |
|---|---|---|---|---|---|
| 7,579 | 179 | 3,395 | 3,157 | 552 | 1,690 |
| Protein | Taxonomy | beta-lactams (IC50) | moxifloxacin (IC50) |
|---|---|---|---|
| DNA gyrase subunit B | Staphylococcus aureus | 5.1033 | |
| DNA gyrase subunit A | Escherichia coli K-12 | 1.4 | |
| DNA gyrase subunit B | Escherichia coli K-12 | 1.4 | |
| DNA topoisomerase 4 subunit A | Staphylococcus aureus | 0.8 | |
| DNA gyrase subunit A | Staphylococcus aureus | 7.25 | |
| DNA gyrase subunit B | Mycobacterium tuberculosis H37Rv | 8.525 | |
| DNA gyrase subunit A | Mycobacterium tuberculosis H37Rv | 8.66 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (38.10) | 29.6817 |
| 2010's | 12 (57.14) | 24.3611 |
| 2020's | 1 (4.76) | 2.80 |
| Authors | Studies |
|---|---|
| Carryn, S; Mingeot-Leclercq, MP; Tulkens, PM; Van Bambeke, F | 1 |
| Goldstein, EJ | 1 |
| Behra-Miellet, J; Dubreuil, L; Jumas-Bilak, E | 1 |
| Karpov, OI; Strekachev, AIu; Zaĭtsev, AA | 1 |
| Farny, K; Michault, A; Picot, S; Simac, C | 1 |
| Krause, R; Laferl, H; Széll, M; Wenisch, C | 1 |
| Dimopoulos, G; Falagas, ME; Giannopoulou, KP; Grammatikos, AP; Karageorgopoulos, DE | 1 |
| Galani, I; Giamarellos-Bourboulis, EJ; Giamarellou, H; Kanellakopoulou, K; Sarafis, P | 1 |
| An, MM; Cao, YB; Gao, PH; Jiang, YY; Shen, H; Zou, Z | 1 |
| Ewig, S; Hecker, H; Marre, R; Suttorp, N; Welte, T | 1 |
| Engler, C; Harris, P; Norton, R | 1 |
| Bauer, TT; Ernen, C; Hauptmeier, BM; Hecht, J; Lepper, PM; Nüesch, E; Ott, SR; Pletz, MW; Welte, T | 1 |
| Carbonnelle, S; De Bel, A; Dediste, A; Glupczynski, Y; Huang, TD; Jacobs, F; Jordens, P; Lismond, A; Schatt, P; Tulkens, PM; Van Bambeke, F; Verhaegen, J; Verschuren, F | 1 |
| Dalhoff, A; Schubert, S | 1 |
| Alder, J; Arvis, P; De Waele, JJ; Hampel, B; Jensen, M; Reimnitz, P; Tellado, JM | 1 |
| Al-Nawas, B; Callaway, AS; Karbach, J; Wagner, W; Willershausen, B | 1 |
| Bettoli, V; Join-Lambert, O; Nassif, A | 1 |
| Deshpande, D; Gumbo, T; Nuermberger, E; Pasipanodya, JG; Srivastava, S; Swaminathan, S | 1 |
| Adamzik, M; Asmussen, S; Karlik, J; Peters, J; Rahmel, T; Steinmann, J | 1 |
| Cheng, A; Chuang, YC; Sheng, WH; Wang, JT; Yang, JJ | 1 |
| Fukui, M; Marumo, S; Shirata, M; Tamai, K; Yoshimoto, Y | 1 |
4 review(s) available for beta-lactams and moxifloxacin
| Article | Year |
|---|---|
[New approaches to antibacterial therapy of infections in the surgical practice].
Topics: Abdominal Abscess; Aza Compounds; Bacterial Infections; beta-Lactams; Community-Acquired Infections; Cross Infection; Ertapenem; Fluoroquinolones; Humans; Lactams; Moxifloxacin; Quinolines; Randomized Controlled Trials as Topic; Surgical Wound Infection | 2003 |
Fluoroquinolones compared with beta-lactam antibiotics for the treatment of acute bacterial sinusitis: a meta-analysis of randomized controlled trials.
Topics: Acute Disease; Anti-Bacterial Agents; Aza Compounds; beta-Lactams; Fluoroquinolones; Humans; Moxifloxacin; Pneumococcal Infections; Quinolines; Randomized Controlled Trials as Topic; Sinusitis | 2008 |
Moxifloxacin monotherapy versus beta-lactam-based standard therapy for community-acquired pneumonia: a meta-analysis of randomised controlled trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; beta-Lactams; Community-Acquired Infections; Fluoroquinolones; Humans; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Quinolines; Treatment Outcome; Young Adult | 2010 |
Antibiotic Treatment of Hidradenitis Suppurativa.
Topics: Anti-Bacterial Agents; beta-Lactams; Ceftriaxone; Clindamycin; Drug Therapy, Combination; Ertapenem; Fluoroquinolones; Hidradenitis Suppurativa; Humans; Imipenem; Maintenance Chemotherapy; Metronidazole; Moxifloxacin; Remission Induction; Rifampin | 2016 |
4 trial(s) available for beta-lactams and moxifloxacin
| Article | Year |
|---|---|
Moxifloxacin versus standard therapy in patients with pneumonia hospitalized after failure of preclinical anti-infective treatment.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; beta-Lactams; Doxycycline; Drug Therapy, Combination; Female; Fluoroquinolones; Hospitalization; Humans; Levofloxacin; Macrolides; Male; Middle Aged; Moxifloxacin; Ofloxacin; Pneumonia, Bacterial; Quinolines; Treatment Failure | 2006 |
Moxifloxacin monotherapy versus beta-lactam-based standard therapy for community-acquired pneumonia: a meta-analysis of randomised controlled trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; beta-Lactams; Community-Acquired Infections; Fluoroquinolones; Humans; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Quinolines; Treatment Outcome; Young Adult | 2010 |
Treatment failure in pneumonia: impact of antibiotic treatment and cost analysis.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; beta-Lactams; Community-Acquired Infections; Drug Therapy, Combination; Female; Fluoroquinolones; Health Care Costs; Humans; Length of Stay; Macrolides; Male; Middle Aged; Moxifloxacin; Pneumonia; Quinolines; Treatment Failure | 2012 |
Randomised clinical trial of moxifloxacin versus ertapenem in complicated intra-abdominal infections: results of the PROMISE study.
Topics: Administration, Intravenous; Adult; Aged; Anti-Bacterial Agents; Aza Compounds; beta-Lactams; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Ertapenem; Female; Fluoroquinolones; Humans; Incidence; Intraabdominal Infections; Male; Middle Aged; Moxifloxacin; Prospective Studies; Quinolines; Treatment Outcome | 2013 |
14 other study(ies) available for beta-lactams and moxifloxacin
| Article | Year |
|---|---|
Comparative intracellular (THP-1 macrophage) and extracellular activities of beta-lactams, azithromycin, gentamicin, and fluoroquinolones against Listeria monocytogenes at clinically relevant concentrations.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Azithromycin; beta-Lactams; Ciprofloxacin; Fluoroquinolones; Gentamicins; Humans; Listeria monocytogenes; Macrophages; Microbial Sensitivity Tests; Moxifloxacin; Quinolines | 2002 |
Intra-abdominal anaerobic infections: bacteriology and therapeutic potential of newer antimicrobial carbapenem, fluoroquinolone, and desfluoroquinolone therapeutic agents.
Topics: Abdominal Abscess; Anti-Bacterial Agents; Aza Compounds; Bacteremia; Bacteria, Anaerobic; Bacteroides fragilis; Bacteroides Infections; beta-Lactams; Carbapenems; Clinical Trials as Topic; Ertapenem; Fluoroquinolones; Gemifloxacin; Humans; Indoles; Lactams; Moxifloxacin; Naphthyridines; Quinolines; Quinolones | 2002 |
Antianaerobic activity of moxifloxacin compared with that of ofloxacin, ciprofloxacin, clindamycin, metronidazole and beta-lactams.
Topics: Anaerobiosis; Anti-Bacterial Agents; Aza Compounds; Bacterial Infections; beta-Lactams; Ciprofloxacin; Clindamycin; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Metronidazole; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines | 2002 |
[Antimicrobial resistance of Streptococcus pneumoniae strains isolated in the Reunion Island during 2004].
Topics: Aza Compounds; beta-Lactams; Cephalosporin Resistance; Cephalosporins; Chloramphenicol; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Humans; Ketolides; Moxifloxacin; Penicillin Resistance; Quinolines; Retrospective Studies; Reunion; Rifampin; Streptococcal Infections; Streptococcus pneumoniae; Tetracycline; Trimethoprim, Sulfamethoxazole Drug Combination | 2006 |
In vitro synergism of beta-lactams with ciprofloxacin and moxifloxacin against genetically distinct multidrug-resistant isolates of Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Aza Compounds; beta-Lactams; Ciprofloxacin; DNA Fingerprinting; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Synergism; Electrophoresis, Gel, Pulsed-Field; Fluoroquinolones; Microbial Viability; Moxifloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines; Time Factors | 2008 |
Moxifloxacin monotherapy versus ß-lactam mono- or combination therapy in hospitalized patients with community-acquired pneumonia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; beta-Lactams; Community-Acquired Infections; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Quinolines; Survival Analysis; Treatment Outcome; Young Adult | 2011 |
Comparative in vitro susceptibility of Burkholderia pseudomallei to doripenem, ertapenem, tigecycline and moxifloxacin.
Topics: Anti-Bacterial Agents; Aza Compounds; beta-Lactams; Burkholderia pseudomallei; Carbapenems; Doripenem; Ertapenem; Fluoroquinolones; Humans; Melioidosis; Microbial Sensitivity Tests; Minocycline; Moxifloxacin; Quinolines; Tigecycline | 2011 |
Antimicrobial susceptibility of Streptococcus pneumoniae isolates from vaccinated and non-vaccinated patients with a clinically confirmed diagnosis of community-acquired pneumonia in Belgium.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Belgium; beta-Lactams; Child; Child, Preschool; Clarithromycin; Community-Acquired Infections; Comorbidity; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Pneumonia, Pneumococcal; Quinolines; Streptococcus pneumoniae; Vaccination; Young Adult | 2012 |
Activity of moxifloxacin, imipenem, and ertapenem against Escherichia coli, Enterobacter cloacae, Enterococcus faecalis, and Bacteroides fragilis in monocultures and mixed cultures in an in vitro pharmacokinetic/pharmacodynamic model simulating concentrat
Topics: Anti-Bacterial Agents; Aza Compounds; Bacterial Load; Bacteroides fragilis; beta-Lactams; Colony Count, Microbial; Enterobacter cloacae; Enterococcus faecalis; Ertapenem; Escherichia coli; Fluoroquinolones; Humans; Imipenem; Microbial Sensitivity Tests; Models, Statistical; Moxifloxacin; Pancreas; Pancreatitis, Acute Necrotizing; Quinolines; Regression Analysis | 2012 |
Multiple resistance to betalactam antibiotics, azithromycin or moxifloxacin in implant associated bacteria.
Topics: Aza Compounds; Azithromycin; Bacteria; beta-Lactams; Dental Implants; Drug Resistance, Microbial; Drug Resistance, Multiple; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Quinolines | 2013 |
A Faropenem, Linezolid, and Moxifloxacin Regimen for Both Drug-Susceptible and Multidrug-Resistant Tuberculosis in Children: FLAME Path on the Milky Way.
Topics: Antitubercular Agents; Bacterial Load; beta-Lactams; Child; Computer Simulation; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fluoroquinolones; Humans; Linezolid; Microbial Sensitivity Tests; Models, Theoretical; Moxifloxacin; Mycobacterium tuberculosis; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2016 |
Moxifloxacin monotherapy versus combination therapy in patients with severe community-acquired pneumonia evoked ARDS.
Topics: Adult; Alanine Transaminase; Anti-Bacterial Agents; Aspartate Aminotransferases; beta-Lactams; Bilirubin; Community-Acquired Infections; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Intensive Care Units; Length of Stay; Male; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Respiratory Distress Syndrome; Retrospective Studies | 2017 |
Impact of broad-spectrum antimicrobial treatment on the ecology of intestinal flora.
Topics: Acinetobacter baumannii; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; beta-Lactams; Cephalosporins; Cross Infection; Drug Resistance, Bacterial; Enterobacteriaceae; Ertapenem; Feces; Female; Fluoroquinolones; Gastrointestinal Microbiome; Humans; Male; Microbial Viability; Middle Aged; Moxifloxacin; Pseudomonas aeruginosa; Taiwan | 2018 |
In vitro efficacy of combinations of eight antimicrobial agents against Mycobacteroides abscessus complex.
Topics: Actinomycetales Infections; Amikacin; Anti-Bacterial Agents; beta-Lactams; Clarithromycin; Doxycycline; Humans; Imipenem; Linezolid; Microbial Sensitivity Tests; Moxifloxacin; Mycobacteriaceae; Sequence Analysis, DNA | 2020 |